Of these, PD-L1 TPS is an FDA-approved biomarker for use of ICIs.11 Simplified comorbidity score, an alternative for Charlson Comorbidity Index, was chosen to adjust for the association of other comorbidities with survival outcomes.10 Despite limitations related to nonadjustment for other potential confounding variables, such as obesity and tumor genomic alterations (eg, EGFR-altered NSCLC), our results merit close consideration in light of increasing use of ICIs in the real-world among patients who might not otherwise be considered treatment eligible. This evidence concerns the gene EGFR and neoplasm.